Please assess the completion status of the following clinical trial:

Trial Title: Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with moderate to severe Crohn's Disease.~* Failed prior infliximab therapy.~* Patient is judged to be in generally good health as determined by the principal investigator.~Exclusion Criteria:~* Previous treatment with adalimumab.~* Patient considered by the investigator, for any reason, to be an unsuitable candidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).